Until recently, indications for standard-of-care molecular testing in colorectal carcinomas included testing for KRAS mutational status as a predictor of response to anti–epidermal growth factor receptor (EGFR) agents such as cetuximab [4]. Here, EGFR is linked to colorectal carcinoma.